NOVEL SNAKE TOXIN

• US 20090285825A1
• Filed: 12/22/2005
• Published: 11/19/2009
• Est. Priority Date: 12/22/2004
• Status: Abandoned Application

• Current Assignee: National University of Singapore
• Original Assignee: National University of Singapore
• Inventors: Kini, Manjunatha Ramachandra, Hon Wong, Peter Tsun, Teo, Chung Pin, Fung, Yuh Fen, Kumar, Prakash Pallathadka
• Application Number:
  US11/721,286
• Publication Number:
  US 20090285825A1
• Time in Patent Office: Days
• US Class Current: 424/141.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/38 Antigens from snakes
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/46 from vertebrates

Abstract

This invention is in the field of snake venom and the invention provides a novel snake toxin protein and nucleic acids encoding the same. Also, provided are various uses and compositions based on the discovery of the novel snake toxin.

Claims

1. A protein, selected from the group consisting of:

(a) a protein comprising the sequence SEQ ID NO;

1;

(b) a protein comprising the sequence SEQ ID NO;

3;

(c) a protein comprising the sequence SEQ ID NO;

5;

(d) a protein comprising the sequence SEQ ID NO;

7;

or

(e) (i) an allelic variant of a protein according to (a), (b), (c) or (d);

(ii) a functional equivalent of a protein according to (a), (b), (c), (d) or (e)(i) which functional equivalent retains the ability to induce at least one of hypolocomotion or hyperalgesia, or which functional equivalent has an antigenic determinant in common with a protein according to (a) s (b), (c), (d) or (e)(i);

(iii) an active fragment of a protein according to (a), (b), (c), (d), (e)(i) or (e)(ii) which active fragment retains the ability to induce at least one of hypolocomotion or hyperalgesia, or which active fragment has an antigenic determinant in common with a protein according to (a), (b), (c), (d), (e)(i) or (e)(ii);

or

(iv) a fusion protein comprising a protein according to (a), (b), (c), (d), (e)(i), (e)(ii) or (e)(iii).

2. A nucleic acid molecule which encodes the protein according to the claim 1.

3. A vector that contains the nucleic acid molecule according to claim 2.

4. A host cell transformed with the vector according to claim 3.

5. A method of producing the protein according to claim 1, the method comprising culturing a host cell according to claim 4.

6. A method of producing the protein according to claim 1, the method comprising performing chemical synthesis of the protein.

7. The method according to claim 6, wherein said chemical synthesis is a solid phase peptide synthesis or combinatorial chemistry.

8. A method of making a polyclonal or monoclonal antibody, capable of binding the protein according to claim 1, wherein the method comprises immunizing an animal with a protein according to claim 1 and harvesting antibodies from the animal or harvesting cells from the animal for use in producing monoclonal antibodies.

9. An antibody which binds to the protein according to claim 1.

10. A method of producing an antivenom against a protein according to claim 1 wherein the method comprises immunizing an animal with a protein according to claim 1 and harvesting antibodies from the animal for use as the antivenom.

11. The method according to claim 10 wherein the animal is a horse, goat, sheep or bird.

12. An antivenom effective against a protein of claim 1.

14. A pharmaceutical composition comprising the protein according to claim 1, the nucleic acid molecule according to claim 2, the vector according to claim 3, the host cell according to claim 4, the antibody according to claim 9, or the antivenom produced by the method according to claim 11.

18. A method of sedating an animal comprising administering the protein according to claim 1, the nucleic acid molecule according to claim 2, the vector according to claim 3, or the host cell according to claim 4.

19. A method of treating a patient with a neurological or muscular disease comprising administering to the patient the protein according to claim 1, the nucleic acid molecule according to claim 2, the vector according to claim 3, or the host cell according to claim 4.

13. (canceled)

15. (canceled)

16. (canceled)

17. (canceled)

20. (canceled)